Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Britannia Pharmaceuticals Ltd.

Division of Stada Arzneimittel AG
www.britannia-pharm.co.uk

Latest From Britannia Pharmaceuticals Ltd.

Cynapsus Wants To Offer Parkinson’s Patients A Friendlier Apomorphine Option

Sublingual film formulation of apomorphine, just moving into Phase III, would address “off” episodes with fewer side effect issues and easier administration than the current injectable version.

BioPharmaceutical Canada

Bioequivalence To Duopa Could Mean Quick Path To Market For NeuroDerm In Parkinson’s

With several companies working on new Parkinson’s therapies to maintain therapeutic levels of levodopa, NeuroDerm thinks it has a formulation that will offer similar benefits to AbbVie’s Duopa, with less invasive therapy.

BioPharmaceutical United States

Parkinson’s Disease Market Snapshot: A Wave Of Drugs For Symptoms

Several drugs that address symptoms of the neurodegenerative disease are moving closer to market, presenting interesting commercial opportunities despite the fact that a disease-modifying breakthrough remains elusive.

BioPharmaceutical Clinical Trials

Novartis seeks Japan Stalevo nod as Parkinson's rivals multiply

Responding to rapidly rising competition in the Parkinson's disease sector in Japan, Novartis has filed for the approval in the country of its single pill combination of carbidopa, levodopa and entacapone (licensed from Orion).

Neurology Japan
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
    • Drug Delivery
      • Nasal
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Stada Arzneimittel AG
  • Senior Management
  • Simon Collis, Global Sales & Bus. Dev. Dir.
  • Contact Info
  • Britannia Pharmaceuticals Ltd.
    Phone: (44) 118 920 9500
    200 Longwater Ave.
    Green Park
    Reading, RG2 6GP
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register